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Abstract
Brain metastases are highly resistant to chemotherapy. Metastatic tumor cells are known to exploit the host micro-
environment for their growth and survival. We report here that melanoma brain metastases are surrounded and in-
filtrated by activated astrocytes, and we hypothesized that these astrocytes can play a role similar to their established
ability to protect neurons from apoptosis. In coculture experiments, astrocytes, but not fibroblasts, reduced apoptosis
in human melanoma cells treated with various chemotherapeutic drugs. This chemoprotective effect was dependent
on physical contact and gap junctional communication between astrocytes and tumor cells. Moreover, the protective
effect of astrocytes resulted from their sequestering calcium from the cytoplasm of tumor cells. These data suggest
that brain tumors can, in principle, harness the neuroprotective effects of reactive astrocytes for their own survival
and implicate a heretofore unrecognized mechanism for resistance in brain metastasis that might be of relevance in
the clinic.
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Introduction
In the United States, up to 40% of cancer patients develop brain me-
tastasis [1]. The top five primary tumors that lead to brain metastasis
are lung, breast, melanoma, renal, and colorectal tumors [2]. The me-
dian survival duration of untreated patients is 1 to 2 months, and che-
motherapy, in conjunction with surgery and radiation therapy, extends
survival to only 4 to 6 months [1]. Poor prognosis in these patients is
primarily due to chemoresistance [3]. Traditionally, resistance of brain
metastasis to chemotherapy has been attributed to the blood-brain barrier
(BBB), which prevents toxic substances from reaching the brain paren-
chyma [4,5]. However, recent studies have revealed that the BBB is not
intact in brain metastasis because metastatic tumor cells release vascular
permeability factor also known as vascular endothelial growth factor
[4,6]. Moreover, more than 70% of brain metastasis cases exhibit en-
hanced lesions onmagnetic resonance imaging due to leakage of contrast
agent from blood vessels, thus indicating BBB permeability [7].
The outcome of brain metastasis in patients depends on multiple in-
teractions between tumor cells and the tumor microenvironment, which
metastatic cells exploit to their advantage [8,9]. Astrocytes, the predomi-
nant cells in the brain maintain homeostasis of the brain microenviron-
ment [10,11]. They transport various nutrients from the circulation to
the neurons, participate in neural signal transduction, and buffer the
ionic balance of the extracellular matrix [12–15]. Under pathological
conditions, such as trauma, ischemia, and neurodegenerative disease,
astrocytes became activated, as indicated by the up-regulation of glial
fibrillary acidic protein (GFAP) [16]. These reactive astrocytes have been
shown to protect neurons from injury induced apoptosis [11,17,18].
Abbreviations: BBB, blood-brain barrier; CBX, carbenoxolone; GFAP, glial fibrillary
acidic protein; GFP, green fluorescent protein; GJC, gap junctional communication;
5-FU, 5-fluorouracil; PE, phycoerythrin; RFP, red fluorescent protein
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These observations raise the intriguing possibility that reactive astro-
cytes can also protect melanoma cells in brain metastases from cyto-
toxicity induced by chemotherapeutic drugs. To test this hypothesis,
we studied the sensitivity of various melanoma cells to chemotherapeutic
agents when cocultured with mouse astrocytes or fibroblasts. We con-
clude that astrocytes (but not fibroblasts) significantly reduced apop-
tosis mediated by the chemotherapeutic agents and that the protective
effects of astrocytes resulted from their sequestering calcium from the
cytoplasm of the tumor cells.
Materials and Methods
Mice
Athymic Ncr-nu/nu male mice were purchased from National Can-
cer Institute–Frederick Cancer Research Facility (Frederick, MD).
Animal protocols were approved and supervised by the University of
Texas MD Anderson Cancer Center (Houston, TX) Institutional Ani-
mal Care and Use Committee.
Mouse Model of Melanoma Brain Metastasis
Human metastatic melanoma cells were introduced into the brain
parenchyma of mice through internal carotid artery injection under
microscopy as described previously [19]. After mice developed neuro-
logical symptoms (e.g., circling), mice were killed, and the brain tissue
was harvested for analysis.
Cell Lines, Cell Cultures, and Reagents
The human metastatic melanoma cell lines A375P, DM-4 (from
lymph node metastasis specimens) and TXM-13 (from brain metastasis
specimens) were all established at theMD Anderson Cancer Center. All
melanoma cell lines were recovered from frozen stocks and cultured as
previously described [20]. Immortal mouse astrocytes were established
in our laboratory [21]. Calcein-AM, Fura-2AM, Fluo-3AM, Hochest
33342, BAPTA-AM, and connexin 43 antibodies were purchased from
Invitrogen (Carlsbad, CA). CBX and propidium iodide were purchased
from Sigma (St. Louis, MO). GFAP antibodies were purchased from
Biocare Medical (Concord, CA). Paclitaxel was purchased from Bristol-
Myers Squibb (New York, NY), cisplatin was from SICOR Pharma-
ceuticals (Irvine, CA), and 5-fluorouracil (5-FU) was from American
Pharmaceutical Partners (Schaumburg, IL).
Scanning Electron Microscopy of Tumor Cells and Astrocytes
A375P human melanoma cells and murine astrocytes (1:1 ratio) were
plated on sterilized glass coverslips in 24-well plates at a density of 2.4 ×
104 cells/well. After 48 hours, the samples were processed as described
previously [22].
Chemoprotection Experiment by Flow Cytometry Analysis
Tumor cells were cultured alone or with green fluorescent protein
(GFP)–expressing astrocytes at a ratio of 1:1. After being incubated
for 72 hours with chemotherapeutic drugs, floating and adherent cells
were harvested and fixed with 70% ethanol. The propidium iodide
staining procedure was performed as described previously [23]. The
fluorescein isothiocyanate (FITC)–propidium iodide protocol was used
to separate the GFP-expressing, FITC-positive astrocyte population
from FITC-negative tumor cells (Figure 1). This was followed by an
analysis of apoptosis in control untreated tumor cells, followed by tumor
cells and tumor-astrocyte cocultured samples incubated with chemo-
therapeutic agents. Apoptotic tumor cells were assessed as the fraction
of cells in the sub-G0 region. Untreated and apoptotic tumor cells were
cultured alone and used as controls. Apoptosis in response to chemo-
therapeutic drugs in astrocytes cultured alone or cocultured with tumor
cells was performed as described above for tumor cells. In this case,
apoptosis was assessed as the fraction of GFP-positive cells in the sub-G0
region (Figure 1).
Transwell Experiment
Transwell Boyden Chamber inserts (0.4-μm pore size; Costar,
Corning, NY) were seeded with astrocytes (105 cells). Tumor cells
Figure 1. Flow cytometry protocol to analyze the tumor cell death. The FITC–propidium iodide protocol was used to analyze the cell
cycle of tumor cells (nonlabeled) and astrocytes (GFP-labeled) separately. The sub-G0 and -G1 regions were defined as the percentage
of cell death. (A) The GFP gate is able to distinguish tumor cells (bottom) from astrocytes (top). (B) The cell cycle of astrocytes (FITC-
positive because of GFP labeling). (C) The cell cycle of tumor cells (FITC-negative).
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(105 cells) were seeded in the bottom well. Tumor cells were treated
with chemotherapeutic drugs and analyzed as described above.
Immunohistochemical Staining
The expression of GFAP and connexin 43 in specimens was analyzed
by immunostaining using GFAP (1:50) and Connexin 43 antibodies
(1:50) in conjunction with peroxidase (human specimens) or fluores-
cent (mouse specimens and cell staining) antimouse secondary anti-
body (1:500). Nuclei were stained using Hochest 33342.
Evaluation of Gap Junctional Communication By
Dye Transfer
The dye transfer assay was performed as described previously [24]. In
brief, astrocytes (donor cells) were labeled with calcein-AM (5 μM) for
30 minutes at 37°C. Tumor cells (recipient cells) were labeled with DiI
(5 μM) for 30 minutes at 37°C. Astrocytes and tumor cells were plated
(1:50) in six-well plates. After 6 hours, the cells were harvested and
analyzed by fluorescence-activated cell sorting (FACS) to determine the
fraction of DiI-positive tumor cells containing calcein.
Knock Down of Connexin 43 in Astrocytes by Short
Hairpin RNA
Connexin 43 short hairpin RNA (shRNA; target sequence: shRNA1,
–GAAGTTCAAGTACGGGATT– and shRNA 2, –CCATCTTCAT-
CATCTTCAT–) and a nontargeting shRNA (target sequence: TTCT-
CCGAACGTGTCACGT)were usedwith the lentiviral systemdeveloped
and kindly provided by Didier Trono (Ecole Polytechnique Fédérale de
Lausanne, Lausanne, Switzerland) as described previously [25].
Western Blot
Total cell extracts (sonification) were separated by gradient (4%-12%)
Nu–polyacrylamide gel electrophoresis and transferred to membranes
using an iBlot dry blot analysis (Invitrogen). Connexin 43 was detected
with antibodies (1:500), using β-actin antibodies (1:3000) as the load-
ing control.
Real-time Polymerase Chain Reaction (Quantitative
Polymerase Chain Reaction)
Reverse transcription was performed using the high-capacity RNA-
to-cDNA kit (Applied Biosystems, Carlsbad, CA). The gene expression
assay for connexin 43 was from Applied Biosystems (assay ID:
Mm00439105_m1), with human 18S as the endogenous control (Ap-
plied Biosystems). Real-time polymerase chain reaction was performed
with the ABI Prism 3000 spectrometer (Applied Biosystems). The rela-
tive CT was used for comparison.
Cytoplasmic Calcium Measurement
Temporal analysis of cytosolic Ca2+. At different time intervals,
melanoma cells treated with apoptotic agents were labeled with Fura-
2AM (1 μM, 30 minutes at 37°C). The cells were then washed and
relative changes to cytosolic Ca2+ were expressed as the ratio of fluores-
cence intensities at 340 and 380 nm (λem = 510 nm) using untreated
cells as the control [26].
Flow cytometric analysis of cytosolic Ca2+. A375P melanoma cells
were cultured alone or with red fluorescent protein (RFP)–expressing
astrocytes. Paclitaxel (10 ng/ml) was added to the culture medium with
or without the gap junctional communication (GJC) inhibitor CBX
(100 μM). After a 24-hour incubation, the cells were labeled with the
Ca2+ indicator, Fluo-3AM (2μM, 30minutes, 37°C), and washed twice
with phosphate-buffered saline. Cytoplasmic Ca2+ levels in the harvested
cells were determined by flow cytometry using the FITC–phycoerythrin
(PE) protocol, which allowed the exclusion of RFP-positive (red) astro-
cytes from the analysis (Figure 2). Cytoplasmic Ca2+ in tumor cells
(PE-negative population) was assessed as the mean FITC fluorescence.
Data were expressed as the relative change in cytoplasmic calcium com-
pared with control tumor cells that had not been treated with chemo-
therapeutic agents.
Statistical Analysis
Data are presented as the mean ± SEM. A statistical comparison of
treatment sets was performed using the Student’s t test.
Results and Discussion
In the first set of experiments, we injected human A375 parental cells
[20] into the internal carotid artery of nude mice [19]. Mice exhibiting
neurological symptoms were killed, and their brain tissue was processed
for immunohistological analysis, which revealed that, similar to clinical
specimen of human melanoma brain metastases (Figure 3, A–C ), the
experimental melanoma brain metastases (Figure 3, D–F ) were sur-
rounded and infiltrated by GFAP-positive reactive astrocytes.
In the next set of in vitro studies, we used an immortalized astrocyte
cell line derived from the brain of H-2K b-tsA58 mice [21] and co-
cultured these astrocytes with melanoma cells. A scanning electron
microscopic examination revealed that the astrocytes formed direct con-
tacts with tumor cells through multiple podia. In some areas, astrocytes
and tumor cells formed a seamless structure, which resembled GJC
(Figure 3G ).
Next, we evaluated chemotherapy-induced apoptosis in tumor cells
in the absence and presence of astrocytes. Coculture with astrocytes
dramatically reduced 5-FU–induced apoptosis in the humanmelanoma
Figure 2. Flow cytometry to analyze the cytoplasmic calcium lev-
els of tumor cells. A375P melanoma cells were cultured alone or
with astrocytes (labeled with RFP). Paclitaxel was added to the
culture medium, with or without GJC blocker CBX (100 μM). After
treatment for 12 hours, calcium indicator Fluo-3AM (2 μM) was
added to the medium and incubated for 30 minutes, followed by
two washes with phosphate-buffered saline. Cytoplasmic calcium
levels were determined by flow cytometry analysis, using the FITC-
PE protocol to exclude PE-positive astrocytes.
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Figure 4. Astrocytes protect melanoma cells from chemotherapy by a mechanism that requires direct physical contact. (A–C) Human mela-
noma cells were cultured alone or cocultured with GFP-expressing astrocytes (Ast.). After a 72-hour incubation with P-glycoprotein–sensitive
(paclitaxel) or –insensitive (5-FU and cisplatin) chemotherapeutic drugs, the cells were harvested and ethanol-fixed, and the apoptotic index
of the tumor cells (GFP-negative population) was determined by FACS using the propidium iodide protocol. (C) Physical separation of astro-
cytes and tumor cells using a transwell membrane (0.4-μm pore size) abolished the protective effect. (D) Astrocytes cultured alone or co-
cultured with human melanoma cells (TXM13) did not undergo apoptosis after incubation with chemotherapeutic drugs under conditions
similar to that described above. (E) Substituting NIH3T3 fibroblasts for astrocytes in (A) and (B) failed to demonstrate protection of tumor cells
from chemotherapy. Data are the mean of three experiments. Error bars represent SEM. *P < .01, **P > .05.
Figure 3. Melanoma-astrocyte interaction. (A–C) A human specimen of melanoma brain metastasis in a tumor free zone (A) shows only
sporadic expression of GFAP (brown); in the tumor zone (B), many reactive astrocytes surround and infiltrate tumor lesions; (C) higher
magnification of reactive astrocytes in the tumor zone. (D–F) Mouse model of brain metastasis produced by human metastatic melanoma
cell lines A375P (D) and TXM13 (E, F). Reactive astrocytes are stained in red, and nuclei are stained in blue. Asterisk (*) indicates tumorzone; star (★), tumor-free zone. (F) Higher magnification of reactive astrocytes from (E). (G) Scanning electron microscopic image of astro-
cytes (A) and A375P melanoma cells (T) shows direct physical contact between the astrocytes (extending pods-feet) and tumor cells. Note
the seamless structure between the astrocytes and tumor cells indicated by the arrowhead.
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cells A375P, TXM13, and DM-4 by 78.6%, 62.8%, and 69.7%, re-
spectively (Figure 4A). This protection was not specific to the chemo-
therapeutic agent because astrocytes demonstrated similar reductions
in cytotoxicity against A375P, TXM13, and DM-4 cells with cisplatin
(79.7%, 77.2%, and 59.2%, respectively; Figure 4B) and paclitaxel
(43.5%, 56.8%, and 82%, respectively; Figure 4C). Similar results were
also obtained using the MTT cell viability assay [27] (data not shown).
Astrocytes cultured alone or cocultured with melanoma cells did not
undergo apoptosis when incubated with the chemotherapeutic agents
under similar conditions (Figure 4D). To determine whether protection
by astrocytes required secreted factors or direct physical contact, we re-
peated the experiments described above but separated the astrocytes
from tumor cells by a transwell membrane (0.4-μm pore size). Under
these conditions, the astrocytes failed to protect the tumor cells from
chemotherapy-induced apoptosis (Figure 4C ). Substituting murine
NIH3T3 fibroblasts for astrocytes in the coculture experiments failed
to provide protection (Figure 4E). Moreover, because astrocytes protect
melanoma cells against both P-glycoprotein–sensitive (paclitaxel) and
insensitive (5-FU and cisplatin) drugs [1], the above observations sug-
gest that astrocyte-tumor interactions, rather than P-glycoprotein ex-
pression, are a foremost indicator of chemoresistance in melanoma
brain metastases [28]. The chemoprotective nature of astrocytes was
not restricted to melanoma cells. The protective effect was also demon-
strated for human breast cancer cells, human lung cancer cells, and even
3T3 fibroblasts [29].
GJC channels, which directly connect the cytoplasm between
adjacent cells, have been shown to be involved in the transmission of
survival and apoptotic signals between neighboring cells [30,31]. Both
astrocytes and melanoma cells expressed connexin 43, the major GJC
at the cell surface (Figure 5A). The functionality of GJC was evaluated
Figure 5. Astrocytes protect melanoma cells through GJC. (A) Expression of connexin 43 in A375P melanoma cells and astrocytes by
immunofluorescence staining. (B) Functional assay of GJC. DiI-labeled A375P melanoma cells (B1) and calcein-AM–labeled astrocytes
(B2) were coincubated for 6 hours in a CO2 incubator, followed by FACS analysis (B3). Note that tumor cells are shifted to the right along
the FITC axis, indicating the presence of calcein in these cells. The separation of astrocytes and tumor cells by a transwell membrane did
not result in calcein-positive tumor cells (B4), underscoring the requirement of direct physical contact for dye transfer. (C) A375P mela-
noma cells were cultured either alone or together with astrocytes and were incubated for 72 hours with paclitaxel in the absence or
presence of the GJC inhibitor, CBX. This was followed by an analysis of the apoptotic index by FACS. Although CBX did not affect
apoptosis in single cultures of tumor cells or astrocytes, the inhibitor caused significant reversal of tumor cell protection in the coculture
group. (D and E) Western blot analysis (D) and quantitative polymerase chain reaction (E) of connexin 43 expression in astrocytes trans-
duced with lentivirus containing nontargeted (NT) and targeted (shRNA-1 and shRNA-2) sequences. (F) Chemoprotection of tumor cells
from paclitaxel-induced apoptosis was partly reversed in Ast-shRNA-1 astrocytes when compared with Ast-NT controls and was deter-
mined by coculture experiments. Data are the mean of three experiments. Error bars represent SEM. *P < .05.
752 Astrocytes Protect Tumor Cells From Chemotherapy Lin et al. Neoplasia Vol. 12, No. 9, 2010
using the dye transfer assay (Figure 5B), which measures the transfer of
fluorescent calcein from the astrocytes to the tumor cells; this process
can occur only by direct cell-to-cell transfer [30–32]. To determine
whether astrocyte-mediated protection of tumor cells occurred through
GJC, cocultures were assessed for tumor cell apoptosis in the absence or
presence of carbenoxolone (CBX), a specific inhibitor of GJC channels
[33,34]. Under these conditions, CBX completely reversed the pro-
tection (Figure 5C ). To confirm the participation of GJC in tumor
cell protection, we knocked down expression of connexin 43 in astro-
cytes [35]. Two shRNA sequences specific against connexin 43 [36]
were inserted into lentiviral vectors and transduced into astrocytes.
Stable cell lines were established, and the knockdown was confirmed
at the protein (Figure 5D) and transcription (Figure 5E) levels. Analy-
sis of tumor cell apoptosis in coculture experiments with connexin
43–deficient astrocytes (Ast-shRNA-1) revealed increased sensitivity
of these tumors to chemotherapy when compared with nontargeted
astrocytes (Ast-NT) (Figure 5F ). Whereas the small interfering RNA
approach precludes complete reversal of protection, these data, taken
together with the results of the inhibitor experiments (Figure 5, B and
C ), underscore the importance of GJC to astrocytes’ protection of
tumor cells from chemotherapy.
Calcium, one of the most important second messengers transmitted
through GJC channels [37], has been shown to play a causal role in
cell death [38]. Temporal analysis of melanoma cells incubated with
chemotherapeutic agents revealed an increase in cytoplasmic calcium
that is followed by the appearance of fragmented DNA, one of the hall-
marks of apoptosis (Figure 6A). The importance of cytoplasmic calcium
to melanoma apoptosis is demonstrated by our finding that its chela-
tion with BAPTA inhibited paclitaxel-induced cell death (Figure 6B).
Analysis of cytoplasmic Ca2+ in paclitaxel-treated tumor cells by flow
cytometry revealed that coculture with astrocytes significantly reduced
cytoplasmic calcium levels when compared with tumor cells incubated
with paclitaxel in the absence of astrocytes (Figure 6C). Furthermore,
this effect was reversed by the inclusion of the GJC channel blocker
CBX in the culture medium (Figure 6C ). Although we cannot rule
out the participation of other molecules by these experiments, these
data implicate Ca2+ sequestration through GJC channels as a key mecha-
nism by which astrocytes protect the tumor cells from chemotherapy
(Figure 6D).
Resistance to chemotherapy is one of the major causes of mortality
in patients with brain metastasis. Until now, this resistance has been
primarily attributed to the impermeable nature of the BBB and the
expression of P-glycoprotein by metastatic cells, but we provide here a
novel alternate mechanism that requires direct physical connections
between activated astrocytes and tumor cells in the brain tumor micro-
environment. Taken together, the data presented here underscore the
ability of metastatic brain tumors to harness and adopt the neuro-
protective properties of resident astrocytes for their own survival. Thus,
successful treatment of brain metastasis will require chemotherapy
in combination with agents that selectively interfere with the GJC
Figure 6. Astrocytes sequester cytoplasmic calcium from tumor
cells through GJC. (A) Temporal analysis of cytoplasmic calcium
(relative Fura-2 fluorescence) and DNA fragmentation (propidium
iodide analysis) in A375P cells incubated with paclitaxel (10 ng/ml).
Data are expressed relative to the initial (t=0 hour) values. (B) A375P
cells were preincubated with the indicated concentrations of BAPTA-
AM before incubation with paclitaxel (10 ng/ml), and the apoptotic
index was determined as described earlier. (C) RFP-expressing astro-
cytes were cocultured with tumor cells and incubated with paclitaxel
(10 ng/ml) for 12 hours in the absence or presence of CBX. The cells
were then labeledwith Fluo-3AMandharvested, and cytoplasmic cal-
cium levels in the tumor cells (RFP-negative)were determined by flow
cytometry. Data are presented relative to untreated control tumor
cells. Note that inhibition of GJC between tumor cells and the astro-
cytes with CBX (100 μM) resulted in higher cytoplasmic calcium lev-
els compared with paclitaxel-treated tumor cells alone. (D) Proposed
working model for astrocytes’ protection of tumor cell apoptosis.
When tumor cells cultured alonewere treatedwith chemotherapeutic
drugs, an accumulation of cytoplasmic calcium (green circles) led to
tumor apoptosis. Coculture of tumor cells with astrocytes, however,
resulted in GJC channels between these cells that served as con-
duits for sequestration and, hence, depletion of calcium and other
proapoptotic molecules from the tumor cytoplasm. Alternatively,
astrocyte-derived survival factors and signals could be transferred
to tumor cells, thereby reducing tumor calcium overload.
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channels between these tumor cells and tumor-associated astrocytes.
This could potentially be achieved by targeted therapies that are deliv-
ered to tumor-associated astrocytes using GFAP antibodies or short
nucleotide sequences complementary to GFAP messenger RNA [39].
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